Showing 1,522 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental HIV treatments

Merck's HIV program closer to regulator's doorstep with two phase 3 trials showing efficacy comparable to existing meds

Editor's pick
FierceBiotech
31 October 2021
Pharmaceutical industry

Thailand’s switch to dolutegravir: more generic versions needed!

Editor's pick
Medicines Patent Pool
31 October 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
Access to healthcare

New study confirms MPP licences save money and lives

Editor's pick
Medicines Patent Pool
26 October 2021
PrEP policies & guidelines

Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union

Editor's pick
Gilead press release
22 October 2021
Access to healthcare

2021 HIV Market Report: The state of the HIV market in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
12 October 2021
HIV treatment for children & young people

ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV

Editor's pick
ViiV Healthcare press release
5 October 2021
PrEP science

Most switches to Descovy PrEP are probably unnecessary and some may be harmful

News
1 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
Injectable & long-acting PrEP

FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

Editor's pick
ViiV Healthcare press release
28 September 2021
Pharmaceutical industry

Gilead, Merck and others slapped with 'pay-for-delay' lawsuits over lucrative HIV and cholesterol meds

Editor's pick
FiercePharma
27 September 2021
HIV treatment for children & young people

Unitaid, the Clinton Health Access Initiative, and Laurus Labs announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children

Editor's pick
Clinton Health Access Initiative
13 September 2021
Access to healthcare

HIV treatment dolutegravir arrives in more upper-middle-income countries

Editor's pick
Medicines Patent Pool
3 September 2021
New & experimental HIV treatments

CytoDyn’s previous HIV filing snafu now on better course after FDA sets them straight

Editor's pick
Fierce Biotech
16 August 2021
Pharmaceutical industry

Negative innovation: when patents are bad for patients

Editor's pick
Nature
12 August 2021
Access to healthcare

Pricing agreement brings HIV drug darunavir within reach of LMICs

Editor's pick
Devex
29 July 2021
Access to healthcare

Innovative agreement launches affordable, optimal second-line HIV treatment in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
28 July 2021
Access to healthcare

HIV: Breakthrough in cryptococcal meningitis gives Gilead opportunity to fulfil promise to scale up access to key drug

Editor's pick
MSF
22 July 2021
Access to healthcare

Advocates Are Unhappy with the Global AIDS Agenda's Drug Patent Language

Editor's pick
TheBody
18 July 2021
Generic medicines

Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths

News
9 July 2021
PrEP programmes & uptake

US: ‘This will shut us down’: HIV prevention clinics brace for Gilead reimbursement cuts

Editor's pick
NBC News
8 July 2021
Pharmaceutical industry

Gilead files long-acting HIV med for patients running out of options

Editor's pick
FierceBiotech
1 July 2021
Pharmaceutical industry

GSK puts long-acting injectables at heart of HIV growth plans, downplays threat of oral rival from Gilead and Merck

Editor's pick
FiercePharma
29 June 2021